RT Journal Article
SR Electronic
T1 Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2759
OP 2766
VO 36
IS 6
A1 BRÄUTIGAM, KAREN
A1 MITZLAFF, KATHARINA
A1 UEBEL, LISA
A1 KÖSTER, FRANK
A1 POLACK, STEPHAN
A1 PERVAN, MASCHA
A1 STEINERT, GUNNAR
A1 RODY, ACHIM
A1 LIEDTKE, CORNELIA
YR 2016
UL http://ar.iiarjournals.org/content/36/6/2759.abstract
AB Background/Aim: Diagnosis of triple-negative breast cancer (TNBC) is associated with adverse prognosis, particularly in cases of chemotherapy resistance. The goal of this analysis was to compare TNBC vs. non-TNBC cell lines and those of distinct TNBC subtypes with regard to sensitivity to eribulin in vitro. Materials and Methods: Breast cancer cell lines were subjected to cell-viability assays, apoptosis analyses, migration and invasion experiments, and quantitative real-time polymerase chain reaction after exposure to eribulin. Results: Eribulin reduced cell viability in TNBC and non-TNBC cell lines in the sub-nanomolar range. Furthermore, exposure to eribulin induced apoptosis and decreased the rate of migration and invasion. Genes known to induce malignant transformation were differentially expressed after eribulin treatment. Conclusion: Eribulin had a strong antiproliferative effect on breast cancer cell lines, although we did not observe a significant difference between TNBC and non-TNBC cell lines with regard to sensitivity to eribulin.